26218727
BACKGROUND	Juvderm Voluma XC ( VYC-20L ) is approved in the United States for correction of age-related volume loss in the midface region in adults .
OBJECTIVE	To characterize the effects of VYC-20L in 3 midface subregions based on injection volumes .
METHODS	In this single-blind controlled trial , subjects with midface volume deficit received VYC-20L in 1 of 3 facial subregions ( zygomaticomalar , anteromedial cheek , and submalar ) , with touch-up treatment available 30 days later .
METHODS	Responders achieved 1-point improvement on the Mid-Face Volume Deficit Scale ( MFVDS ) , analyzed by facial subregion and stratified by injection volume quartiles .
METHODS	Subject satisfaction and safety were assessed .
RESULTS	The treatment arm comprised 235 subjects aged 35 to 65 years .
RESULTS	Month 6 MFVDS responder rates were 75.5 % for zygomaticomalar , 83.2 % for anteromedial cheek , and 76.9 % for submalar subregions .
RESULTS	Higher responder rates were observed with increasing injection volume quartiles for each subregion .
RESULTS	Similar median injection volumes ( 2.0 mL total ) of VYC-20L provided correction durations of 15 to 24 months : 24 months for anteromedial cheek , 19 months for zygomaticomalar , and 15 months for submalar subregions .
RESULTS	Subject satisfaction was high across injection volume quartiles .
RESULTS	No unanticipated treatment-site adverse reactions occurred .
CONCLUSIONS	VYC-20L is effective at restoring midface volume , with high subject satisfaction and an acceptable safety profile .

